G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.19 USD
+0.20 (6.69%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 161 - 180 ( 356 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Positive Rintodestrant Combination Data in ASCO Abstract
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Phase 2 PRESERVE 4 Study of Cosela in NSCLC Patients Previously Treated with Checkpoint Inhibitors Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21: Key Word--EXECUTE On the COSELA Launch and New Clinical Trials
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21 Results; Cosela Launch Progressing Nicely; Five Potential Label Expansion Studies Could be Underway by Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial of Cosela in TNBC Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Virtual Analyst and Investor Summit Focuses on Cosela Launch and Potential for SCLC Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
COSELA Kick Off: Spare the Marrow, Spear the Tumor
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Discusses COSELA Campaign: Spare the Marrow, Spear the Tumor
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Included in NCCN Oncology Guidelines. Raising Revenue.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Our Covered Companies at the 33rd ROTH Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T